A Phase 2 interventional study of collagenase clostridium histolyticum in Edematous Fibrosclerotic Panniculopathy, Cellulite and Laxity; Skin, sponsored by Endo Pharmaceuticals. Completed at 3 sites in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-28.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
This study is designed to investigate the safety and efficacy of collagenase clostridium histolyticum (CCH) for the treatment of mild to moderate edematous fibrosclerotic panniculopathy (cellulite) in participants with moderate to severe dermal laxity in the buttocks or thighs with comparison between two (2) different CCH injection techniques.
71 studies on the registry are indexed under Cellulite; 3 are open to participants now.
This study's enrollment of 35 is close to the median of 34 across 65 interventional studies indexed under Cellulite.
Browse Cellulite studies →Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have either both buttocks or both posterolateral thighs with:
Exclusion Criteria:
Has evidence of abnormalities, as judged by the investigator, in any of the following: physical examination findings, (ECG), clinical laboratory values, or vital signs.
The sponsor's medical monitor will be required to review the results for confirmation of eligibility in the case of any of the following: abnormalities in electrocardiograms indicating interval (QTc) prolongation of 470 milliseconds or greater; and clinical laboratory values of liver enzymes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area)
Drug: collagenase clostridium histolyticum
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
Drug: collagenase clostridium histolyticum
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
Drug: collagenase clostridium histolyticum
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
Drug: collagenase clostridium histolyticum
Delivered via uniform grid injection techniques.
Also known as: EN3835, CCH
Percentage of 1-Level Responders (+1 or Better Score) on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for Either Buttock or Either Thigh
I-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level I-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the I-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
Time frame: Day 180
Percentage of 1-Level Responders (+1 or Better Score) on the I-GAIS for Either Buttock or Either Thigh
I-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level I-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the I-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
Time frame: Days 28, 56, 84, 112, and 140
Percentage of 1-Level Responders (+1 or Better Score) on the Subject Global Aesthetic Improvement Scale (S-GAIS) for Either Buttock or Either Thigh
S-GAIS assessments were based on digital photographs, and were performed separately for each of 2 treatment areas. S-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the participant ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level S-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the S-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
Time frame: Days 28, 56, 84, 112, 140, and 180
Change From Baseline in Body-Q Appraisal of Cellulite Total Score
The Body-Q Appraisal of Cellulite is a subset of 11 questions from the Body-Q questionnaire developed to measure participant perceptions of weight loss and/or body contouring. Total score is the sum of all 11 question scores. The minimum possible total score is 11 and the maximum possible total score is 44. Higher scores indicate the individual is less bothered by their cellulite.
Time frame: Baseline, Day 180
Change From Baseline in Hexsel Cellulite Severity Scale (CSS) Subsection D Severity Score
Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite using a 4-point scale from a low of 0 to high of 3: 0 (absence of laxity, flaccidity, or sagging skin), 1 (slight draped appearance), 2 (moderate draped appearance), and 3 (severe draped appearance). The investigator or qualified designee used the Hexsel CSS Subsection D to assess the severity of dermal laxity in each buttock or each thigh independently. A decrease from baseline indicated a better outcome.
Time frame: Baseline, Days 28, 56, 84, 112,140, and 180
Percentage of Participants Positive for Anti-AUX-I and Anti-AUX-II Antibodies
Blood samples were collected to assess anti-clostridial class I collagenase (AUX-I) and anti-Clostridial class II collagenase (AUX-II) antibody levels. The percentage of participants who were positive for anti-AUX-I and anti-AUX-II antibodies are presented.
Time frame: Day 180
Percentage of Participants Positive for Neutralizing Antibodies to AUX-I and AUX-II
Blood samples were collected to assess neutralizing antibodies to AUX-I and AUX-II. The percentage of participants who were positive for neutralizing antibodies to AUX-I and AUX-II are presented.
Time frame: Day 180
| Milestone | Uniform 0.1-mL (Milliliter) 1-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thighs) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thighs) |
|---|---|---|---|---|
| Started | 7 | 9 | 9 | 10 |
| Completed | 7 | 8 | 8 | 10 |
| Not completed | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
I-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level I-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the I-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
| percentage of participants | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thighs) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thighs) |
|---|---|---|---|---|
| Percentage of 1-Level Responders (+1 or Better Score) on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for Either Buttock or Either Thigh | 85.7 (42.13 to 99.64) | 87.5 (47.35 to 99.68) | 75.0 (34.91 to 96.81) | 80.0 (44.39 to 97.48) |
I-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level I-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the I-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
| percentage of participants | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thighs) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thighs) |
|---|---|---|---|---|
| Day 28 | 71.4 (29.04 to 96.33) | 44.4 (13.70 to 78.80) | 77.8 (39.99 to 97.19) | 77.8 (39.99 to 97.19) |
| Day 56 | 85.7 (42.13 to 99.64) | 62.5 (24.49 to 91.48) | 88.9 (51.75 to 99.72) | 88.9 (51.75 to 99.72) |
| Day 84 | 57.1 (18.41 to 90.10) | 75.0 (34.91 to 96.81) | 77.8 (39.99 to 97.19) | 70.0 (34.75 to 93.33) |
| Day 112 | 85.7 (42.13 to 99.64) | 50.0 (15.70 to 84.30) | 77.8 (39.99 to 97.19) | 80.0 (44.39 to 97.48) |
| Day 140 | 71.4 (29.04 to 96.33) | 75.0 (34.91 to 96.81) | 75.0 (34.91 to 96.81) | 80.0 (44.39 to 97.48) |
S-GAIS assessments were based on digital photographs, and were performed separately for each of 2 treatment areas. S-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the participant ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level S-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the S-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.
| percentage of participants | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thighs) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thighs) |
|---|---|---|---|---|
| Day 28 | 71.4 (29.04 to 96.33) | 44.4 (13.70 to 78.80) | 66.7 (29.93 to 92.51) | 66.7 (29.93 to 92.51) |
| Day 56 | 85.7 (42.13 to 99.64) | 75.0 (34.91 to 96.81) | 88.9 (51.75 to 99.72) | 88.9 (51.75 to 99.72) |
| Day 84 | 71.4 (29.04 to 96.33) | 87.5 (47.35 to 99.68) | 55.6 (21.20 to 86.30) | 70.0 (34.75 to 93.33) |
| Day 112 | 85.7 (42.13 to 99.64) | 62.5 (24.49 to 91.48) | 55.6 (21.20 to 86.30) | 70.0 (34.75 to 93.33) |
| Day 140 | 71.4 (29.04 to 96.33) | 87.5 (47.35 to 99.68) | 62.5 (24.49 to 91.48) | 70.0 (34.75 to 93.33) |
| Day 180 | 85.7 (42.13 to 99.64) | 100.0 (NA to NA) | 62.5 (24.49 to 91.48) | 90.0 (55.50 to 99.75) |
The Body-Q Appraisal of Cellulite is a subset of 11 questions from the Body-Q questionnaire developed to measure participant perceptions of weight loss and/or body contouring. Total score is the sum of all 11 question scores. The minimum possible total score is 11 and the maximum possible total score is 44. Higher scores indicate the individual is less bothered by their cellulite.
| units on a scale | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thighs) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thighs) |
|---|---|---|---|---|
| Change From Baseline in Body-Q Appraisal of Cellulite Total Score | 13.4 ± 11.12 | 13.6 ± 9.94 | 10.0 ± 5.81 | 6.4 ± 10.56 |
Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite using a 4-point scale from a low of 0 to high of 3: 0 (absence of laxity, flaccidity, or sagging skin), 1 (slight draped appearance), 2 (moderate draped appearance), and 3 (severe draped appearance). The investigator or qualified designee used the Hexsel CSS Subsection D to assess the severity of dermal laxity in each buttock or each thigh independently. A decrease from baseline indicated a better outcome.
| units on a scale | Uniform 0.1-mL 1-Aliqout Grid Injection Technique (Buttocks) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thighs) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thighs) |
|---|---|---|---|---|
| Day 28 Left Treatment Area | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 28 Right Treatment Area | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 56 Left Treatment Area | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 56 Right Treatment Area | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 84 Left Treatment Area | -0.1 ± 0.38 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 84 Right Treatment Area | -0.1 ± 0.38 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 112 Left Treatment Area | -0.1 ± 0.38 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 112 Right Treatment Area | -0.1 ± 0.38 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 140 Left Treatment Area | -0.4 ± 0.53 | -0.1 ± 0.35 | 0.0 ± 0.00 | -0.2 ± 0.42 |
| Day 140 Right Treatment Area | -0.3 ± 0.49 | -0.1 ± 0.35 | -0.1 ± 0.35 | -0.2 ± 0.42 |
| Day 180 Left Treatment Area | -0.3 ± 0.49 | -0.1 ± 0.64 | -0.1 ± 0.35 | -0.6 ± 0.52 |
| Day 180 Right Treatment Area | -0.3 ± 0.49 | -0.1 ± 0.64 | -0.1 ± 0.35 | -0.5 ± 0.53 |
Blood samples were collected to assess anti-clostridial class I collagenase (AUX-I) and anti-Clostridial class II collagenase (AUX-II) antibody levels. The percentage of participants who were positive for anti-AUX-I and anti-AUX-II antibodies are presented.
| percentage of participants | CCH: Overall Participants |
|---|---|
| Anti-AUX-I Antibodies | 100 |
| Anti-AUX-II Antibodies | 100 |
Blood samples were collected to assess neutralizing antibodies to AUX-I and AUX-II. The percentage of participants who were positive for neutralizing antibodies to AUX-I and AUX-II are presented.
| percentage of participants | CCH: Overall Participants |
|---|---|
| Neutralizing antibodies to AUX-I | 87.5 |
| Neutralizing antibodies to AUX-II | 84.4 |
Collected over Day 1 (after dosing) through Day 180. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttocks or Thighs) | 0/16 (0%) | 0/16 (0%) | 16/16 (100%) |
| Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks or Thighs) | 0/19 (0%) | 0/19 (0%) | 19/19 (100%) |
| Event | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttocks or Thighs) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttocks or Thighs) |
|---|---|---|
| Injection site bruisingGeneral disorders | 16/16 | 19/19 |
| Injection site painGeneral disorders | 10/16 | 13/19 |
| Injection site swellingGeneral disorders | 10/16 | 10/19 |
| Injection site pruritusGeneral disorders | 2/16 | 2/19 |
| Injection site discolourationGeneral disorders | 1/16 | 1/19 |
| Injection site urticariaGeneral disorders | 1/16 | 0/19 |
| Ear infectionInfections and infestations | 1/16 | 0/19 |
| AlcoholismPsychiatric disorders | 1/16 | 0/19 |
| FatigueGeneral disorders | 0/16 | 1/19 |
| Implant site inflammationGeneral disorders | 0/16 | 1/19 |
Safety Population: All enrolled participants who received at least 1 injection of CCH. Participants who received injection in the buttock or thigh are combined for each injection technique.
| Age, Continuous(years) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttock or Thigh) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttock or Thigh) | Total |
|---|---|---|---|
| Mean | 40.73 ± 8.844 | 42.51 ± 6.225 | 41.70 ± 7.472 |
| Sex: Female, Male(Participants) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttock or Thigh) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttock or Thigh) | Total |
|---|---|---|---|
| Female | 16 | 19 | 35 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttock or Thigh) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttock or Thigh) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 4 |
| Not Hispanic or Latino | 16 | 15 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Buttock or Thigh) | Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttock or Thigh) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 13 | 18 | 31 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase